Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107863574 | 10786357 | 4 | F | 20131015 | 20160624 | 20150211 | 20160707 | EXP | JP-ALEXION PHARMACEUTICALS INC-A201500420 | ALEXION | 56.67 | YR | M | Y | 0.00000 | 20160707 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107863574 | 10786357 | 1 | PS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, QW | 5400 | MG | AA8443B01 | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | /wk | |||
| 107863574 | 10786357 | 2 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, SINGLE | 5400 | MG | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QD | ||||
| 107863574 | 10786357 | 3 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 1200 MG, Q2W | 5400 | MG | AA8443B03 | 125166 | 1200 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||
| 107863574 | 10786357 | 4 | C | CEFAMEZIN /00288502/ | CEFAZOLIN | 1 | Intravenous (not otherwise specified) | 1 G, QD | 8 | G | 0 | 1 | G | QD | |||||
| 107863574 | 10786357 | 5 | C | CRAVIT | LEVOFLOXACIN | 1 | Oral | 250 MG, QD | 3500 | MG | 0 | 250 | MG | QD | |||||
| 107863574 | 10786357 | 6 | C | PREDONINE | PREDNISOLONEPREDNISOLONE ACETATEPREDNISOLONE SODIUM SUCCINATE | 1 | Oral | 40 MG, QD | 0 | 40 | MG | QD | |||||||
| 107863574 | 10786357 | 7 | C | ADALAT | NIFEDIPINE | 1 | Oral | 40-80 MG, QD | 0 | QD | |||||||||
| 107863574 | 10786357 | 8 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 2.5 MG, QD | 0 | 2.5 | MG | QD | |||||||
| 107863574 | 10786357 | 9 | C | LEXOTAN | BROMAZEPAM | 1 | Oral | 5 MG, QD | 0 | 5 | MG | QD | |||||||
| 107863574 | 10786357 | 10 | C | LEXOTAN | BROMAZEPAM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 107863574 | 10786357 | 1 | Haemolytic uraemic syndrome |
| 107863574 | 10786357 | 4 | Infection |
| 107863574 | 10786357 | 5 | Infection |
| 107863574 | 10786357 | 6 | Haemolytic uraemic syndrome |
| 107863574 | 10786357 | 7 | Hypertension |
| 107863574 | 10786357 | 8 | Product used for unknown indication |
| 107863574 | 10786357 | 9 | Insomnia |
| 107863574 | 10786357 | 10 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 107863574 | 10786357 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 107863574 | 10786357 | Beta haemolytic streptococcal infection | |
| 107863574 | 10786357 | Depression | |
| 107863574 | 10786357 | Dyslipidaemia | |
| 107863574 | 10786357 | Hypertension |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 107863574 | 10786357 | 1 | 20131010 | 20131115 | 0 | |
| 107863574 | 10786357 | 2 | 20131115 | 20131115 | 0 | |
| 107863574 | 10786357 | 3 | 20131129 | 0 | ||
| 107863574 | 10786357 | 4 | 20131015 | 20131022 | 0 | |
| 107863574 | 10786357 | 5 | 20131010 | 20131023 | 0 | |
| 107863574 | 10786357 | 6 | 20130930 | 0 | ||
| 107863574 | 10786357 | 7 | 20131004 | 20131025 | 0 | |
| 107863574 | 10786357 | 8 | 20131129 | 20150303 | 0 | |
| 107863574 | 10786357 | 9 | 20140110 | 201502 | 0 |